Market Place
Sourcing Support
Tremfya is 1st IL-23 Inhibitor with Subcutaneous in Crohn`s Disease
28 Oct 2024 //
PR NEWSWIRE
Positive results for J&J’s Tremfya in plaque psoriasis
26 Oct 2024 //
PRESS RELEASE
J&J`s Tremya, Lilly`s Ebglyss score in new patient groups
25 Oct 2024 //
FIERCE PHARMA
J&J Showcases Neuropsychiatry Portfolio At Psych Congress
24 Oct 2024 //
PR NEWSWIRE
DARZALEX® Approved for Newly Diagnosed Multiple Myeloma Patients
23 Oct 2024 //
GLOBENEWSWIRE
DOJ files motion to derail J&J`s Texas two-step talc settlement
22 Oct 2024 //
FIERCE PHARMA
J&J’s Tremfya May Set New Standard In Crohn’s Disease
21 Oct 2024 //
FINANCIALXPRESS
Accord Healthcare Receives Positive CHMP Opinion for Imuldosa
19 Oct 2024 //
PR NEWSWIRE
New J&J Tremfya ad puts inclusive twist on psoriasis marketing
16 Oct 2024 //
FIERCE PHARMA
J&J must pay 15M to man who says its talc caused his cancer
16 Oct 2024 //
REUTERS
Cancer drug sales lift J&J past Wall Street expectations
15 Oct 2024 //
REUTERS
Johnson & Johnson Reports Q3 2024 Results
15 Oct 2024 //
BUSINESSWIRE
J&J Announces Quarterly Dividend for Fourth Quarter 2024
15 Oct 2024 //
BUSINESSWIRE
Nipocalimab Demonstrates Disease Control In Myasthenia Gravis Study
15 Oct 2024 //
GLOBENEWSWIRE
Forbion`s €2B funds are largest yet, with 30 biotechs to benefit
15 Oct 2024 //
FIERCE BIOTECH
Lilly reports Ph 3 study of mirikizumab compared to ustekinumab for Crohn
15 Oct 2024 //
PR NEWSWIRE
J&J talc bankruptcy in Texas despite `forum-shopping` opposition
11 Oct 2024 //
REUTERS
Johnson & Johnson to Participate in Stifel 2024 Healthcare Conference
10 Oct 2024 //
BUSINESSWIRE
TREMFYA Shows Impressive Results In Crohn`s And Ulcerative Colitis
10 Oct 2024 //
PR NEWSWIRE
J&J Submits DARZALEX SC Quadruplet For Multiple Myeloma To EMA
10 Oct 2024 //
GLOBENEWSWIRE
Johnson & Johnson Completes Acquisition of V-Wave
09 Oct 2024 //
BUSINESSWIRE
J&J discontinues late-stage study for bladder cancer drug
08 Oct 2024 //
REUTERS
J&J drops Ph 2 dengue candidate as part of move away from vaccines
05 Oct 2024 //
FIERCE BIOTECH
Johnson & Johnson To Participate In Guggenheim Healthcare Event
04 Oct 2024 //
BUSINESSWIRE
Innovative Drug Combinations Offer New Hope for Alzheimer`s and More
03 Oct 2024 //
PR NEWSWIRE
J&J`s Erleada shows survival edge over Xtandi in real-world study
02 Oct 2024 //
FIERCE PHARMA
J&J to invest $2 billion for new manufacturing facility in Carolina
02 Oct 2024 //
REUTERS
J&J, Legend`s Carvykti shows 45% survival benefit in myeloma
01 Oct 2024 //
FIERCE PHARMA
J&J gives up controversial 340B rebate plan
01 Oct 2024 //
FIERCE HEALTH
AHF: J&J Retreats From Scheme To Gut 340B Drug Pricing Program
30 Sep 2024 //
BUSINESSWIRE
SciBase announces sale of Nevisense to NIH (US)
27 Sep 2024 //
PR NEWSWIRE
Darzalex Based Maintenance Shows Deep Responses In Multiple Myeloma
27 Sep 2024 //
PR NEWSWIRE
CARVYKTI Extends Overall Survival For Multiple Myeloma Patients
27 Sep 2024 //
PR NEWSWIRE
Novel Combination Of Talvey And Tecvayli Suggest High Response
27 Sep 2024 //
GLOBENEWSWIRE
Darzalex SC Formulation Improves Negativity For Multiple Myeloma
27 Sep 2024 //
GLOBENEWSWIRE
J&J counters Sanofi`s Sarclisa nod with Darzalex data drop
27 Sep 2024 //
FIERCE PHARMA
Bhushan Akshikar appointed as President of OPPI
26 Sep 2024 //
FINANCIALXPRESS
J&J talc opponents decry bankruptcy as "deja vu all over again"
23 Sep 2024 //
REUTERS
Sanofi wins US approval for multiple myeloma drug
23 Sep 2024 //
REUTERS
J&J Unit Files Bankruptcy To Advance $10B Talc Settlement
21 Sep 2024 //
REUTERS
J&J earns 3rd NSCLC nod in 7 months for surging Rybrevant
20 Sep 2024 //
FIERCE PHARMA
DARZALEX based quadruplet regimen receives positive CHMP
20 Sep 2024 //
GLOBENEWSWIRE
Dupixent Recommended for EU Approval by the CHMP
20 Sep 2024 //
GLOBENEWSWIRE
Rybrevant plus standard of care Approved For EGFR-Mutated Lung Cancer
19 Sep 2024 //
PR NEWSWIRE
Ichnos-Glenmark Antibody Outperforms J&J`s Tecvayli In Mice Study
17 Sep 2024 //
FIERCE BIOTECH
J&J talc appeal upends $260M award to Oregon woman with mesothelioma
17 Sep 2024 //
FIERCE PHARMA
TAR-200 Plus Cetrelimab Improves Bladder Cancer Response
16 Sep 2024 //
GLOBENEWSWIRE
ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer
16 Sep 2024 //
#N/A
TAR-200 Plus Cetrelimab Doubles Response In Bladder Cancer
16 Sep 2024 //
PR NEWSWIRE
TAR-200 Shows 84% Complete Response In High-Risk Bladder Cancer
16 Sep 2024 //
GLOBENEWSWIRE
RYBREVANT Plus Chemo Shows 49% Response In Colorectal Cancer
14 Sep 2024 //
GLOBENEWSWIRE
RYBREVANT Plus Chemo Shows Positive OS Trend In EGFR-Mutated Lung Cancer
14 Sep 2024 //
GLOBENEWSWIRE
J&J Seeks EU Approval For Nipocalimab In Myasthenia Gravis
12 Sep 2024 //
GLOBENEWSWIRE
US FDA expands J&J`s psoriasis drug for inflammatory bowel disease
12 Sep 2024 //
REUTERS
Prophylactic Dexamethasone Reduces Reactions In EGFR-Mutated NSCLC
10 Sep 2024 //
GLOBENEWSWIRE
Dexamethasone Reduces RYBREVANT® Infusion Reactions
10 Sep 2024 //
PR NEWSWIRE
Johnson & Johnson consolidates medtech brands under single banner
10 Sep 2024 //
FIERCE BIOTECH
Johnson & Johnson Told To Pay ?35 Lakh Each To Hip Implant Victims
10 Sep 2024 //
ECONOMICTIMES
J&J Bolsters Rybrevant-Lazcluze Case Vs AZ`s Tagrisso With Survival Data
09 Sep 2024 //
FIERCE PHARMA
Johnson & Johnson To Host Third-Quarter Results Call
05 Sep 2024 //
BUSINESSWIRE
